Group Prior Approvals
Applications for treatments excluded from tariff.
Group Prior Approvals
Group Prior Approval
This page is in the process of being updated with accessible versions of the Group Prior Approvals. If you are unable to find the form you require, please email cpicb.prescribingpartnership@nhs.net to request a copy.
Dermatology
- Adalimumab for Severe Localised Psoriasis in Adults - Local Agreement
- TA103, 134, 146 Biologics for Plaque Psoriasis in Adults
- TA177 Alitretinoin for the treatment of severe chronic hand eczema
- TA339 Omalizumab
- TA350 Secukinumab for Plaque Psoriasis in Adults
- TA475 Dimethyl fumerate for the treatment of moderate to severe plaque psoriasis in adults
- TA511 Brodalumab in severe plaque psoriasis
- TA534 Dupilumab for Atopic Dermatitis in Adults
- TA574 Certolizumab for severe plaque psoriasis in adults
- TA575 Tildrakizumab for severe plaque psoriasis in adults
- TA907 Deucravacitinib for Plaque Psoriasis in Adults
- TA958 Ritlecitinib for Severe Alopecia in Adults
- TA986 Lebrikizumab for Atopic Dermatitis in Adults
Endocrinology
- CamAPS FX for Adults and Children with Approved Funding for IPT - Local Agreement
- Continuous Glucose Monitoring For Children and Young People Under 19 years
- Continuous Glucose Monitoring in Adults over 19 years
- Medtronic EWIS 7-day Infusion Set - Local Agreement
- Omnipod 5 Closed Loop System NICE TA151 and Local Agreement
- TA769 Palforzia for Peanut Allergy in Children Aged 4-17 Years
- TA863 Somatrogon for Growth Distrubance in Children and Adolescants Over 3 years
Gastroenterology
- TA329 Biologics for Ulcerative Colitis After Failure of Conventional Treatments in Adults
- TA547 Tofacitinib for Ulcerative Colitis in Adults
- TA828 Ozanimod for Ulcerative Colitis in Adults
- TA856 Upadacitinib for Ulcerative Colitis in Adults
- TA888 Risankizumab for Previously Treated Crohn's Disease in Adults
- TA905 Upadacitinib for Moderately to Severely Active Crohn's Disease in Adults
- TA925 Mirikizumab for Ulcerative Colitis in Adults
- TA956 Etrasimod for Ulcerative Colitis
- TA998 Risankizumab for Previously Treated Ulcerative Colitis in Adults
Haematology
- Rituximab Biosimilar For Idiopathic Thrombocytopenic Purpura in Adults – Local Agreement
- Rituximab Biosimilar For The Initial Treatment of Autoimmune Haemolytic Anaemia in Adults – Local Policy
- Rituximab Biosimilar for The Initial Treatment of Thrombotic Thrombocytopenic Purpura in Adults - Local Agreement
- TA221 Romiplostim for Chronic Immune Thrombocytopenia in Adults
- TA617 Lusutrombopag for severe thrombocytopenia prior to surgery in adults with liver disease
- TA626 Avatrombopag for severe thrombocytopenia prior to surgery in adults with liver disease
- TA697 Andexanet Alfa for Uncontrolled or Life-Threatening GI Bleeding in Adults on Apixaban or Rivaroxaban Treatment
- TA853 Avatrombopag for Primary Chronic Immune Thrombocytopenia in Adults
Miscellaneous
Budesonide for Immunglobulin A Nephropathy (IgAN) in Adults
Liothyronine Sodium 20mcg Inj for thyrotoxic crisis - Local Agreement
TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease in Adults
TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Neurology
- MTG46 gammaCore for cluster headache accessible
- TA659 Galcanezumab for Chronic Migraine in Adults
- TA659 Galcanezumab for Episodic Migraine in Adults
- TA758 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
- TA764 Fremanezumab for Chronic Migraine in Adults
- TA764 Fremanezumab for Episodic Migraine in Adults
- TA862 Erenumab for Chronic Migraine in Adults
- TA862 Erenumab for Episodic Migraine in Adults
- TA871 Eptinezumab for Chronic Migraine in Adults
- TA871 Eptinezumab for Episodic Migraine in Adults
- TA906 Rimegepant for Episodic Migraine in Adults
- TA919 Rimegepant for Treating Migraine in Adults
- TA973 Atogepant for Prevention of Migraine in Adults
Respiratory
Rheumatology
- Abatacept Monotherapy for Rheumatoid Arthritis in Adults - Local Agreement
- Infliximab for Patients with Juvenile Idiopathic Arthritis Transferring to Adult Services - Local Agreement
- Rituximab Biosimilar Monotherapy for Early Intervention in Rheumatoid Arthritis in Adults - Local Policy
- TA175 Infliximab Biosimilar for Moderate Rheumatoid Arthritis in Adults
- TA195, 247, 375, 485 Biologics with Methotrexate (Form A) for Rheumatoid Arthritis in Adults accessible
- TA195, 375 and 485 Biologics for Rheumatoid Arthritis in Adults Monotherapy (Form B)
- TA199 and 220 Biologics for Psoriatic Arthritis in Adults
- TA340 Ustekinumab for Psoriatic Arthritis in Adults
- TA373 Biologics in Juvenile Idiopathic Arthritis
- TA383 and 497 Biologics for Ankylosing Spondilitis and Axial Spondyloarthritis in Adults
- TA407 Secukinumab for Ankylosing Spondylitis in Adults
- TA433 Apremilast for psoriatic arthritis in Adults
- TA445 Certolizumab and Secukinumab for Active Psoriatic Arthritis in Adults
- TA466 Baricinib for Rheumatoid Arthritis in Adults
- TA537 - Ixekizumab for psoriatic arthritis
- TA543 Tofacitinib for Psoriatic Arthritis in Adults
- TA718 Ixekizumab for Ankylosing Spondylitis in Adults
- TA719 Secukinumab for Axial Spondyloarthritis in Adults
- TA768 Upadacitinib for PsA in Adults
- TA861 Upadacitinib for Non-Radiographic Axial Spondyloarthritis in Adults
- TA916 Bimekizumab for Psoriatic Arthritis in Adults
- TA918 Bimekizumab for Axial Spondyloarthritis in Adults
- TA920 Tofacitinib for Ankylosing Spondylitis in Adults